Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How a Zebrafish Could Help Solve the Mysteries of Genetic Brain Disease

By Ohio State University | May 23, 2019

A close look at the rapidly developing zebrafish embryo is helping neuroscientists better understand the potential underpinnings of brain disorders, including autism and schizophrenia.

Researchers at The Ohio State University were interested in understanding changes in neurological development that arise from a genetic defect associated with neurological disease – specifically, the loss of a gene called Protocadherin-19, or PCDH19. The link between the mutation and brain disorders is well-established, but the mechanics of why one might lead to the other have been a mystery.

The new study, published online this month in the journal eNeuro, points to a “clustering” of cellular interactions in the brain that may disrupt normal development and brain health.

“Scientists have discovered hundreds of genes that give rise to schizophrenia, autism and other brain disorders, but nobody knows what specifically goes wrong as a result of these genetic mutations,” said lead researcher James Jontes, an associate professor of neuroscience at Ohio State and member of the university’s Neurological Institute.

“Our goal is to understand the cellular roles of these genes and how defects can lead to developmental changes in the brain.”

Zebrafish, or Danio rerio, are small tropical freshwater fish that appeal to scientists for a handful of reasons. Their embryos are transparent, they develop at warp speed and they share a significant chunk of DNA with people, allowing for an expedient and enlightening examination of developmental changes that could eventually have implications in attempts to thwart human disease.

Jontes and his collaborator, graduate student Sarah Light, wanted to see what happened neurologically when they introduced a PCDH19 mutation into zebrafish.

Using a high-powered microscope that allowed the researchers to watch cellular-level changes over time – an instrument that Jontes made himself – the researchers saw clear differences between embryonic development in normal “wild type” zebrafish and embryonic zebrafish in which they’d eliminated the PCDH19 gene.

“This is the first study to use functional imaging at a single-cell level to explore the effects of a mutation known to cause human neurological disease in a living organism, and we saw obvious differences in the brain architecture of the animals with the mutation,” Jontes said.

“This type of work has the potential to help us understand in more detail the relationships between genes and diseases including autism and epilepsy. We don’t understand exactly what these mutations do to brain structure and development in humans and if we can figure out what they do in fish, that will get us a long way toward some answers.”

Neurons form networks in the brain that are essential to human development, thought, function, behavior and emotion. In the altered zebrafish, the researchers were able to observe neuron-level activity with great detail.

And, with the help of advanced mathematical analysis designed to look for relationships between the neurons and patterns in their activity, they saw that the neurological networks in the zebrafish with the mutation were more connected, or clustered, than in the brains of ordinary zebrafish.

The data was collected between three and six days after fertilization, a period of rapid growth and maturation in zebrafish. By the sixth day after fertilization, zebrafish larvae already are demonstrating behaviors such as hunting for food and swimming.

“We saw lots of interconnections between neurons in the mutant zebrafish. We don’t know exactly what that means, but it could mean that inappropriate connections are occurring between cells that wouldn’t normally interact. Maybe it becomes a problem when too many cells are incorporated into a network of neurons.”

Jontes said neuroscientists are intrigued by the fact that any number of genetic mutations have been linked to a given disease, such as autism.

Work like this could help explain how each of those mutations results in human illness, and that could be an important step toward better treatment, he said.


Filed Under: Neurological Disease

 

Related Articles Read More >

Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE